Sanofi (NASDAQ:SNY) Holdings Lifted by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA raised its position in Sanofi (NASDAQ:SNY - Free Report) by 25.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 194,122 shares of the company's stock after buying an additional 39,044 shares during the period. Massachusetts Financial Services Co. MA's holdings in Sanofi were worth $10,766,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sanofi by 124.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock worth $1,344,000 after purchasing an additional 13,358 shares during the last quarter. Axxcess Wealth Management LLC lifted its stake in shares of Sanofi by 130.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock worth $568,000 after buying an additional 5,794 shares during the last quarter. Ballentine Partners LLC lifted its stake in shares of Sanofi by 68.7% during the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock worth $1,445,000 after buying an additional 10,617 shares during the last quarter. Sowell Financial Services LLC bought a new position in Sanofi during the first quarter worth about $328,000. Finally, Farther Finance Advisors LLC increased its position in Sanofi by 66.2% during the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after acquiring an additional 2,476 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on SNY. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Stock Performance

Shares of Sanofi stock traded up $0.70 during trading hours on Tuesday, hitting $48.63. 691,336 shares of the company were exchanged, compared to its average volume of 2,541,438. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The business has a 50-day moving average of $49.65 and a 200-day moving average of $52.13. The stock has a market capitalization of $119.25 billion, a price-to-earnings ratio of 17.37, a P/E/G ratio of 1.10 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter last year, the company earned $1.78 earnings per share. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. As a group, analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.